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Epithelial–mesenchymal transitionulator of cell differentiation. Cell interactions with neighboring cells and the
extracellular matrix regulate gene expression, cell proliferation, polarity and apoptosis. Apical cell–cell
junctions participate in these processes using different types of proteins, some of them exhibit nuclear and
junctional localization and are called NACos for Nuclear Adhesion Complexes. Tight junctions are one type of
such cell–cell junctions and several signaling complexes have been identiﬁed to associate with them. In
general, expression of tight junction components suppresses proliferation to allow differentiation in a
coordinated manner with adherens junctions and extracellular matrix adhesion. These tight junction
components have been shown to affect several signaling and transcriptional pathways, and changes in the
expression of tight junction proteins are associated with several disease conditions, such as cancer. Here, we
will review how tight junction proteins participate in the regulation of gene expression and cell proliferation,
as well as how they are regulated themselves by different mechanisms involved in gene expression and cell
differentiation.
© 2008 Elsevier B.V. All rights reserved.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 762
2. Tight junction associated proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 762
3. ZO-1 and ZONAB in the control of cell proliferation and gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 762
4. ZONAB and ZO-1 associated proteins and regulation of the ZONAB pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 764
5. ZO-2 and gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 764
6. HuASH1, GEF-H1, cingulin and gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765
7. Regulation of tight junction protein expression. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765
8. Conclusions and perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 766
Acknowledgments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 766
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 766matter@ucl.ac.uk (K. Matter).
ll rights reserved.
762 M.S. Balda, K. Matter / Biochimica et Biophysica Acta 1788 (2009) 761–7671. Introduction
For the development and function of epithelial tissues, the
interactions of epithelial cells with each other and the extracellular
matrix via specializedadhesive structures playa critical role. Therefore,
during the last years a key area of cell and developmental biology has
been to understand how epithelial cells interact with their neighbors
and the extracellular matrix, to regulate intracellular signal transduc-
tion, as well as transcriptional and translational regulatory mechan-
isms of gene expression involved in the control of cell proliferation and
differentiation. The apical epithelial intercellular complex consists of
tight junctions (TJs), adherens junctions, and desmosomes. As
reviewed in other chapters of this series, adherens junctions and
desmosomes are adhesive junctions that are linked to the actin and
intermediateﬁlament cytoskeleton, respectively [1–3]. TJs also interact
with the actin cytoskeleton and function as selective barriers that
restrict paracellular diffusion – the gate function – as well as apical/
basolateral intramembrane diffusion of lipids— the fence function [4–
7]. A fourth type of intercellular junctions are gap junctions, which
allow cell to cell communication via the exchange of small diffusible
molecules [8,9]. At the basal membrane, epithelial cells adhere to the
extracellular matrix mainly via integrins and syndecans [10]. All of
these adhesion complexes consist of particular sets of transmembrane
proteins that interact extracellularly with ligands and intracellularly
with generally large multimeric protein complexes consisting of
cytoskeletal linkers, signal transduction proteins as well as factors
involved in DNA transcription and RNA processing.
The transmission of signals from adhesion complexes occurs
according to two different principles: regulation of signaling cascades
that transmit signals via several intermediates, and regulation of
speciﬁc proteins that shuttle between sites of adhesion at the plasma
membrane and the nucleus, a class of proteins we have previously
proposed to call NACos [11–17].
Wehavepreviously reviewedhowepithelial TJs andcell adhesionuse
thesedual localizationproteins to regulategeneexpression in thecontext
of G1/S phase transition and crosstalkwith Ras signaling [11,18,19]. Here,
we will provide an update on the role of TJs in the regulation of gene
expression and review some recent observations on how the expression
of TJs proteins can be controlled at the transcriptional level.
2. Tight junction associated proteins
The identiﬁcationof TJ associatedproteinshasbeenakeyareaof cell
biology during the last twenty years. Occludin, claudins, tricellulin,
JAMs (Junction Adhesion Molecules), CRB-3 (a human homologue of
Drosophila Crumbs) and Bves (blood vessel/epicardial substance) are
the TJ-associated transmembrane proteins that have been identiﬁed
[7,20–25]. We are only just starting to understand how each of these
transmembrane proteins interacts with components of the cytoplas-
mic plaque and how these interactions affect cell functions.
The cytoplasmic plaque associated with TJs is formed by multiple
adaptor and scaffold proteins (e.g., ZO-1/2/3, PATJ, Pals1, PAR-3 and
PAR-6) as well as different types of signaling components such as GTP-
binding proteins, protein kinases and phosphatases as well as
transcriptional and post-transcriptional regulators [6,19,26,27]. Cyto-
plasmic plaque components interact with the membrane proteins as
well as each other, resulting in a protein network that controls
paracellular permeability, gene expression, junctional dynamics, pro-
liferation andpolarity. Althoughwe start to knowmore about particular
proteins and their interactions and functions, how these proteins work
in thenormal cellularcontextandwhichof their interactionpartners are
relevant for particular functions are still poorly understood.
ZO-1, the ﬁrst TJ protein identiﬁed [28], can serve as a typical
example. It is an adaptor protein that belongs to a family of proteins
that contain different types of protein/protein interaction domains
such as three PDZ and an SH3 domain, a domain homologous to yeastguanylate kinase (GUK domain) and an alternatively spliced large C-
terminal domain that interacts with the actin cytoskeleton [29–31].
Other familymembers include PSD-95 (post-synaptic density-95) and
DlgA (Discs large A), a Drosophila tumor suppressor. ZO-1 interacts
with many different TJ proteins and at least some of these interactions
are mutually exclusive; hence, ZO-1 seems to participate in distinct
protein complexes that also might have distinct functions. Function-
ally, ZO-1 has been linked to both, assembly of functional junctions as
well as signal transduction [26,32–34]. This is not restricted to
vertebrate cells, the Drosophila homologue of ZO-1, Tamou/Polychae-
toid, associates with adherens junctions and regulates dorsal closure,
epithelial migration, and cell fate determination in sensory organs
[35,36], and is required for cell speciﬁcation and rearrangement
during Drosophila tracheal morphogenesis [37]. In agreement, knock-
out of ZO-1 in mice has recently also been shown to cause an
embryonic lethal phenotype associated with defects in yolk sac
angiogenesis and apoptosis of embryonic cells [38].
3. ZO-1 and ZONAB in the control of cell proliferation and gene
expression
Several of the TJ-associated adaptor proteins have been linked to the
regulation of epithelial proliferation, and two of them, ZO-1 and ZO-2,
have been shown to regulate transcription factors (Fig. 1). In the case of
ZO-1, reduced expression correlates with increased proliferation of
epithelial cells and/or transformation. For example, inproliferative cells,
during corneal wound repair and in colorectal epithelial cells trans-
formed by overexpression of beta-catenin, ZO-1 is downregulated
[39,40]. Similarly, ZO-1 is downregulated in breast cancer tissues[41],
in primary andmetastatic pancreatic cancer [42], in brainmicrovascular
endothelial cells fromhumanbrain tumors [43]aswell as severalmodels
of epithelial mesenchymal transition [44–47]. In agreement, increased
expression of ZO-1 in MDCK cells reduces cell proliferation [48].
The mechanism by which ZO-1 regulates proliferation may involve
nuclear translocation as ZO-1 has been reported to accumulate
transiently in the nucleus of proliferating cells. However, the role of
nuclear ZO-1 is not clear as not all investigators have found it in the
nucleus, suggesting that additional unknown parameters might affect
its nuclear distribution [49–54]. In fact, ZO-1 inhibits cell proliferation
outside of the nucleus by cytoplasmic sequestration of the Y-box
transcription factor ZONAB, which interacts with the cell cycle
regulator CDK4 and controls expression of cell cycle regulators such
as cyclin D1 and PCNA [48,50,55]. ZO-1 also interacts with the NaCo
ubinuclein, a protein that interacts with viral transcription factors in
the nucleus and ZO-1 at epithelial TJs [56]. Little is known about the
functional relevance of the interaction between ZO-1 and ubinuclein;
however, it may play a role during differentiation as their interaction
is cell density dependent, similarly to the one with ZONAB.
ZONAB is a Y-box transcription factor, a class of multifunctional
regulators of gene expression and cell proliferation [57,58]. The Y-box
factor family includes DbpA/ZONAB, DbpB/YB-1 and DbpC/contrin.
DbpA and DbpB were originally identiﬁed as DNA binding proteins of
the promoters of EGF receptors and MHC II [59,60]. DbpB/YB-1 is the
most extensively studied Y-box factor. Overexpression of DbpB/YB-1
increases the expression of genes involved in proliferation, including
cyclin A, cyclin B1, EGFR and erbB2 [61–63]. Although DbpB/YB-1 does
not seem to associate with cell junctions as DbpA/ZONAB does [50]
(Matter and Balda, unpublished), the two Y-box factors seem to be
functionally redundant to some extent. Knockout experiments in mice
have shown that ZONAB/MSY3-deﬁcient animals develop normally
but, if combined with a DbpB/YB-1 knockout, die earlier than animals
with a DbpB/YB-1 knockout alone [64]. Nevertheless, the molecular
basis for this redundancy is not known.
ZONAB localizes to TJs, where it binds to the SH3 domain of ZO-1,
and can be in the nucleuswhere it participates in the regulation of gene
expression [48,50]. In MDCK cells, ZONAB's nuclear distribution is
Fig. 1. Tight junction-associated proteins in the control of gene expression and emerging mechanisms that control tight junction protein expression. Indicated are the main
transcriptional pathways discussed in this review. In the upper half, some of the most studied mechanisms that can affect TJ proteins expression are pointed out. In the lower half TJ
proteins are indicated that have been suggested or demonstrated to regulate gene expression. Arrows do not reﬂect direct physical interactions, although in some cases this would be
justiﬁed, but refer to functional interactions. ZO-1, by regulating ZONAB localization, has been linked to decreased erbB-2 but increased cyclin D1 and PCNA expression. Symplekin
can regulate gene expression by it interactionwith ZONAB but also by regulating RNA processing. The interaction of ZO-2 with c-fos/c-jun transcription factors has not been linked to
a particular gene but the onewith c-myc seems to repress cyclin D1 expression. Cingulin can regulate gene expression in a RhoA dependent manner by regulating localization of GEF-
H1 as well as other unidentiﬁed mechanisms.
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by cell density. Low density and proliferating MDCK cells express high
levels of ZONAB and low levels of ZO-1; hence, ZONAB accumulates in
the nucleus as well as TJs. In contrast, high density conﬂuent cells,
express high levels of ZO-1 and low levels of ZONAB, which results in a
predominant junctional localization of the transcription factor. These
observations are supported by experiments demonstrating that if the
nuclear ZONAB pool is reduced either by overexpression of ZO-1 or by
depletion of total ZONAB expression using antisense or RNA-inter-
ference techniques, proliferation ofMDCK cells is reduced [48,50]. This
suggests that the proliferation suppressive function of ZO-1 is based on
the cytoplasmic sequestration of ZONAB. In agreement, the SH3
domain of ZO-1, which binds to ZONAB, is necessary and sufﬁcient to
reduce proliferation [48]. These data indicate that the cell-density
dependent accumulation of ZO-1 at TJs results in the inactivation of the
proliferation-promoting ZONAB pathway.
ZO-1 and ZONAB regulate G1/S phase transition of the cell cycle in
at least two ways. In one pathway, ZONAB interacts with CDK4, a
regulator of G1/S phase transition, which colocalizes with ZO-1 at
junctions [48]. A reduction in the nuclear ZONAB accumulation was
found to reduce the nuclear pool of CDK4 and cyclin D1, and reduced
hyperphosphorylation of the retinoblastoma protein, a nuclear CDK4
substrate [48]. In another pathway, ZONAB functions as a transcription
factor and regulates the expression of cell cycle genes [50,55].
Among theknownZONABtargetgenes are twowell-knowncell cycle
genes. PCNA is one of these genes. Its promoter contains an inverted
CCAAT box sequence, which functions as a ZONAB binding site. PCNA is
an essential eukaryotic DNA replication and repair factor [65,66].
Furthermore, a recent cDNA array analysis suggested that ZONAB
overexpression results in the up-regulation of several components that
either participate in replication (e.g., RFC40 and replication licensing
factors) or in chromatin remodeling (histone H4 andHMG-I) or are part
of thecellularmachinery forDNArepair (e.g.,Rad23AandUBE2A)[55]. It
thus seems that ZONAB promotes S-phase progression by up-regulating
the expression of proteins that are required for DNA replication.Additionally, it is possible that ZONABmight participate in stress-related
signaling responses by up-regulating DNA repair genes.
The PCNA promoter may also serve as an experimental system to
determine howZONAB activates some promoters but represses others.
The PCNA promoter can be transcriptionally regulated by various
oncoproteins and transcription factors, such as adenovirus oncoprotein
E1A, cAMP response element-binding protein (CREB), RFX1 transcrip-
tion factors, the coactivator CREB-binding protein (CBP), tumor
suppressor p107, p53, and E2F [67–69]. The ZONAB binding site is
between the p53 (−237), E2F (−84), and ATF-1 (−52) sites. Thus, it
will be interesting to determine whether these binding sites and the
proteins that bind to them affect each other and ZONAB activity.
The identiﬁcation of cyclin D1 as a ZONAB target gene is of
particular importance as it is unregulated in many tumors. Cyclin D1
plays a central role in cell cycle control, and its expression is regulated
at multiple levels, including transcription, mRNA stability, translation,
and protein turnover [70,71]. Furthermore, the fact that the cyclin D1
promoter contains several cis-acting elements that are controlled by
signaling pathways regulated by cell–extracellular matrix and cell–
cell adhesion, and its regulation involves integrin-linked kinase, focal
adhesion kinase, and beta-catenin [11,72–77] suggests that this
promoter represents an important site for crosstalk between path-
ways originating at different sites of adhesion and, hence, may also
affect cell differentiation. A role of ZO-1 and ZONAB in epithelial
morphogenesis is supported by results from 3D-culture experiments
indicating that manipulation of the ZO-1/ZONAB pathway affects the
morphogenetic potential of MDCK cells [55].
Another ZONAB target gene that might be important for the role of
this transcription factor in epithelial differentiation is the erbB-2proto-
oncogene. Upregulation of erbB-2 has been linked to organ develop-
ment and cell differentiation, as well as in certain cellular contexts to
tumorigenesis [78–80]. Since overexpression of erbB-2 has been
associated with tumorigenesis, it was surprising that overexpression
of ZO-1 reduced cell proliferation but increased endogenous erbB-2
expression.However, the levelsof erbB-2overexpression in cancercells
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parts and correlates with gene ampliﬁcation. Furthermore, increased
levels of erbB2 expression have been observed in other cellswhen they
start to differentiate[81,82] and during mouse development [78–80].
Moreover, overexpression of erbB-2 does not always correlate with
increased cell proliferation or transformation, and the activity of
constitutively active alleles depends on the cellular background and
environment [83,84]. Therefore, by regulating theexpressionof erbB-2,
ZO-1 and ZONAB could be part of a TJ-associated signal transduction
pathway important for differentiation of certain tissues as well as for
cross talk with growth factor pathways. Nevertheless, further studies
are needed not only to characterize the molecular mechanisms
involved in the effect of ZO-1 and ZONAB in epithelial morphogenesis
but also to identify more genes regulated by the pathway.
Since the level of ZO-1 expression can affect the activity of ZONAB,
it is important to understand how expression of ZO-1 is regulated. ZO-
1 is expressed at low levels in proliferating low density MDCK cells
and becomes upregulated with increasing cell density [50]. At least in
part, this appears to be mediated by stabilization of the protein at the
forming junctions since its half-life increases with cell density [85].
Because ZO-1 interacts with several junctional membrane proteins, it
is likely that stabilization is mediated by the junctional accumulation
of transmembrane components. Nevertheless, it is likely that the
contribution of transcriptional mechanisms is also important for the
regulation of ZO-1 expression. For example, ZO-1 mRNA is down-
regulated during corneal wound repair [39], by overexpression of
beta-catenin [40] as well as upon cell transformation induced by Ras
and TGF-beta [44,86–88]. Future studies will have to address whether
and how signaling pathways that regulate ZO-1 expression affect
ZONAB localization and transcriptional activity.
ZO-1 knockout by homologous recombination has recently been
shown to retard TJ assembly in calcium switch experiments in the
mouse mammary epithelial cell line Eph4 with not change in cell
density and proliferation [32]. In agreement, we and others also
observed retardation of TJ formation in MDCK cells upon depletion of
ZO-1 by RNA interference [26,34,89]. In contrast to Eph4 cells, we have
observed increased cell densities in both MDCK and MCF10-A-95 cells
if ZO-1 was down-regulated by RNA interference [48,55], suggesting
that proliferation control in EpH4 cells is differently regulated.
Interestingly, oncogenic Ha-Ras induces increased cell proliferation
in EpH4 mammary epithelial cells only if they were cultivated as
organotypic structures in three-dimensional collagen-Matrigel
matrices but not in standard two-dimensional cultures as in the one
used by Umeda et al. [32], suggesting that EpH4 cell proliferation
depends on the culture condition [84]. It is thus striking that
modulation of the ZO-1/ZONAB pathway only signiﬁcantly affected
the differentiation potential of MDCK cells in three dimensional
cultures and not when grown as monolayers. Therefore, it will be
interesting to test whether ZO-1 knockout in Eph4 cells will have a
stronger phenotype in cell proliferation when cultivated in three-
dimensional collagen-Matrigel matrices. Knockout of ZO-1 inmice has
recently been shown to cause an embryonic lethal phenotype. This
was associated with defects in yolk sac angiogenesis and apoptosis of
embryonic cells [38]. However, what caused lethality and the relevant
downstream pathways are not known.
4. ZONAB and ZO-1 associated proteins and regulation of the
ZONAB pathway
ZONAB interacts with a number of different proteins apart from
ZO-1. The ﬁrst one identiﬁed was CKD4, resulting in regulation of the
nuclear accumulation of the cell cycle kinase [48]. In contrast,
symplekin is another interaction partner and seems to cooperate
with ZONAB in the nucleus.
Symplekin is a nuclear protein that can associate with TJs and has
been linked to the machinery involved in 3′-end processing of pre-mRNA and polyadenylation [90–92] and thereby promotes gene
expression. In agreement, symplekin interacts with HSF-1 (heat shock
inducible transcription factor one) to regulate hsp70 mRNA poly-
adenylation in stressed cells [93]. Although it will be necessary to
characterize other mRNA transcripts that are regulated by symplekin,
this might represent a mechanism by which intercellular junctions
participate in the regulation of mRNA processing.
ZONAB and symplekin form a nuclear complex in kidney and
intestinal epithelial cells. Symplekin depletion by RNA interference
reduces ZONAB nuclear accumulation and transcriptional activity in
colon adenocarcinoma cells, resulting in inhibition of cell proliferation
and reduced of expression the ZONAB-target gene cyclin D1. Thus,
symplekin and ZONAB cooperate in the regulation of transcription, they
promote epithelial proliferation and cyclin D1 expression [94]. ZONAB is
a Y-box factor, a family of proteins that are multifunctional and can
interact with DNA as well as RNA [57]. It is possible that the interaction
between symplekin and ZONAB is not only functionally important for
transcription but also for RNA processing, stability, and/or localization.
Two other proteins have been linked to the regulation of the ZO-1/
ZONAB pathway in the cytoplasm. The ﬁrst was RalA [95]. Ral proteins
aremembers of the Ras superfamily of small GTPases and are involved
in actin cytoskeleton remodeling, cell cycle control, cellular transfor-
mation and vesicle transport. The GTP-bound form of RalA binds to
ZONAB, resulting in inhibition of the transcription factor and
increasing amounts of RalA–ZONAB complexes at cell–cell junctions
with cell conﬂuence. Ral proteins become activated in response to Ras
activation; consequently, oncogenic Ras alleviates transcriptional
repression by ZONAB in a RalA-dependent manner [95]. Because ZO-
1 and RalA interaction results in similar inhibition of ZONAB
transcriptional activity, it will be necessary to further understand in
which cellular context ZO-1 or RalA interaction takes place and
whether RalA also affects ZONAB's transcriptional activity when
ZONAB is an activator instead of repressor of transcription.
A different type of regulator is the heat shock protein Apg-2 that binds
to the SH3-domain of ZO-1 [96]. In agreement with the observation that
theSH3domainofZO-1 is sufﬁcient to inhibitZONABactivation,bindingof
Apg-2 to the SH3domainof ZO-1 activates ZONAB. This seems tobedue to
directcompetitionfor thesameoroverlappingbindingsites.Consequently,
depletion of Apg-2 in MDCK cells not only inhibits ZONAB but also G1/S
phase progression in similarmanner to overexpression of ZO-1 or the SH3
domain.
Apg-2 represents amolecularmechanism that links TJs and ZONAB
to the cellular stress response. Apg-2 coimmunoprecipitates with ZO-
1 and partially localizes to intercellular junctions. In normally cultured
MDCK cells only a small amount of Apg-2 is associated with ZO-1; in
heat shocked cells, however, the interaction with ZO-1 is stimulated,
triggering ZONAB transcriptional activity [96]. Thus, Apg-2 regulates
activation of the ZO-1/ZONAB pathway in response to heat shock.
Apg-2 not only regulates ZONAB activation but also TJ assembly in
calcium switch experiments. The effect of Apg-2 depletion is similar to
the one of ZO-1 depletion, as the consequence of depletion is a kinetic
one; hence, neither ZO-1 nor Apg-2 is required for assembly of
functional TJs [89]. Nevertheless, whether Apg-2 only regulates
junction assembly due to its interaction with ZO-1 is not clear. Apg-
2 depletion has much more drastic consequences on epithelial
morphogenesis in a three-dimensional culture system, in which it is
required for the development of well-organized polarized cysts [89].
Again, the same observations have beenmade for ZO-1 [55]. It remains
to be determined, however, whether ZO-1 is the only functionally
relevant interaction partner of Apg-2 during epithelial morphogenesis
and how their interaction is regulated.
5. ZO-2 and gene expression
ZO-2 is a protein with a similar domain structure to ZO-1 and was
identiﬁed because it binds to the latter protein [85,97]. ZO-2
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also reported to accumulate transiently in the nucleus of proliferating
cells [53,101,102]. ZO-2 as well as MAGI-1 (which is an inverted
MAGUK) and MUPP1 (a multi-PDZ domain protein) have been shown
to bind and inactivate oncogenic viral proteins [51,103,104]. Further-
more, ZO-2 binds to DNA scaffolding factor SAF-B [53] and the
transcription factors Fos, Jun, C/EBP and c-myc (Fig. 1) [105,106].
ZO-2 and c-Myc can be found associated by immunoprecipitation,
and ZO-2 reduces cyclin D1 transcription via an E boxmyc binding site
which also recruits histone deacetylases [106]. It is difﬁcult to
reconciliate these data in a working model in which nuclear
localization of ZO-2 repress cyclin D1 expression but increases cell
proliferation. Therefore, the functionally relevant genes regulated by
nuclear ZO-2 might not include cyclin D1. However, one possible
candidate is M2 pyruvate kinase; expression of which is also
stimulated by nuclear ZO-2 and correlates with increase proliferation
in epithelial and endothelial cells [107]. By regulating the expression
of M2 type pyruvate kinase, ZO-2 might directly contribute to the
switching of metabolic pathways observed in tumor cells (i.e., the
Warburg effect) [108].
An alternative mechanism by which ZO-2 might regulate gene
expression represents ARVCF. ARVCF is an armadillo-repeat protein of
the p120 (catenin) family that can associate with adherens junctions
and translocate to the nucleus [101]. Nuclear translocation can be
mediated by ZO-2 whereas ZO-1 may regulate association with
forming junctions at the plasmamembrane [101]. However, the role of
nuclear ARVCF is not known.
Similar to ZO-1, ZO-2 deﬁciency in mice causes embryonic
lethality. In the absence of ZO-2, embryos show decreased prolifera-
tion at embryonic day 6.5 and increased apoptosis at embryonic day
7.5; they die shortly after implantation due to an arrest in early
gastrulation [109]. Although the molecular mechanisms responsible
for the observed phenotypes is not known, it will be interesting to
analyze gene expression in these embryos to ﬁnd out whether they
have different expression of cyclin D1 and M2 type of pyruvate kinase
as suggested from cell culture experiments. Furthermore, develop-
mental arrest prior to gastrulation has been described for conven-
tional deletion of several cell cycle regulators (e.g. ATR, Chk1, Mad2,
NBS, Rad50, BRCA1, BRCA2, or Rad51) [110]; hence, it could be that ZO-
2 is involved in the regulation of such genes.
The knockout mice studies also led to another interesting
observation. Although they seem to be redundant in junction
formation in tissue culture models, they seem to have non-redundant
roles in mouse development, which are likely to involve their roles in
signal transduction. In contrast, the third ZO protein, ZO-3, does not
seem to play an obvious role in mouse development [109,111].
Nevertheless, ZO-3 is critical for epidermal barrier function in
zebraﬁsh embryos and its expression is decreased in breast cancer
and squamous cell carcinomas [100,112,113]. However, the molecular
mechanisms by which ZO proteins regulate embryonic development
inmouse and cause phenotypes in other experimental systems remain
to be determined. Moreover, many phenotypes of mice deﬁcient in
speciﬁc junction-associated proteins might be mild under standard
conditions, it will be important to test how these animals respond to
challenges such as different types of stress conditions.
6. HuASH1, GEF-H1, cingulin and gene expression
Indirect evidence suggests that several other TJs associated
proteins might play a role in gene expression. HuASH1, the human
homologue of Drosophila ASH1 (absent, small or homeotic discs 1), is
a transcription factor that belongs to the trithorax group and that
participates in the maintenance of expression of segment-speciﬁc
homeotic genes. HuASH1 was found to co-localize with TJ markers by
immunoﬂuorescence [114]. Drosophila ASH1 functions as a histone
methyltransferase, an enzymatic activity involved in chromatinremodeling and gene expression [115]. Recent data suggest a model
in which Drosophila ASH1 is required to coordinate the regulation of
Myc trans-activation targets [116]. Furthermore, mammalian ASH1 is
also a histone methyltransferase that methylates histone H3 in a
subset of genes [117]. Moreover, the C-terminal part of huASH1
interacts with HDAC1 repression complexes [118]. However, how
huASH1 becomes recruited to intercellular junctions and the func-
tional relevance of its junctional association in chromatin remodeling
and gene expression are unknown.
GEF-H1/Lfc, a guanine nucleotide exchange factor speciﬁc for
RhoA, is involved in the regulation of paracellular permeability and
cell proliferation [119,120]. It is well known that RhoA activation
stimulates epithelial cell proliferation, gene expression and differ-
entiation [121–123]. RhoA is downregulated when epithelial cells
reach conﬂuence, resulting in inhibition of signaling pathways that
stimulate proliferation. GEF-H1/Lfc directly interacts with cingulin, a
junctional adaptor. Cingulin binding inhibits RhoA activation and
depletion of cingulin by regulated RNA interference results in RhoA
activation. These results indicate that forming epithelial TJs contribute
to the downregulation of RhoA by inactivating GEF-H1 in a cingulin-
dependent manner, providing a molecular mechanism whereby TJ
formation is linked to inhibition of RhoA signaling and gene
expression [120].
Disruption of the cingulin gene does not affect TJ formation but
alters gene expression in mouse embryoid bodies. The absence of
cingulin increases the levels of ZO-2, occludin, claudin-2, claudin-6
and claudin-7 but decreases ZO-1, which correlates with increased
expression of transcription factors implicated in endodermal differ-
entiation such as GATA-6, GATA-4 and HNF-4alpha [124]. In MDCK
cells, increased claudin-2 expression in response to cingulin depletion
is RhoA-dependent, suggesting that it might bemediated by activation
of GEF-H1 [125]. As Cingulin interacts with ZO-1 and ZO-2 [126], it is
tempting to speculate that cingulin could be indirectly involved in
regulating the functions of ZO-1 and ZO-2 in gene expression.
7. Regulation of tight junction protein expression
Expression of several TJ proteins is upregulated during differentia-
tion-inducing conditions, such as treatment with glucocorticoids, and
is reduced during cancer and epithelial mesenchymal transition.
Therefore, differential expression of TJ protein is likely to contribute to
the regulation of TJ-associated signaling pathways.
Early studies suggested that dexamethasone stimulates functional
TJ structures in hepatoma, mouse mammary epithelial, brain
endothelial and intestinal epithelial cells [127–130]. Glucocorticoid-
induced expression of TJs in mammary epithelial cells involves the
helix–loop–helix protein Id-1 and down-regulation of RhoA by RhoE,
and is counteracted by TGF-alpha signaling [131,132]. In an intestinal
epithelial cell line, glucocorticoid receptors have been shown to
complex to the GRE site on the MLCK promoter, suppressing the TNF-
alpha-induced increase in MLCK gene activity, protein expression, and
subsequent opening of the intestinal TJ barrier [133]. Additionally, a
cellular cascade that includes glucocorticoid-induced protein kinase
and Akt is triggered by glucocorticoid and regulates phosphorylation,
ubiquitination, and degradation of GSK3, which alters beta-catenin
dynamics, leading to the formation of adherens junctions and TJ
sealing [134]. It is tempting to suggest that one or more of the
mechanisms described could be involved in the increased expression
of ZO-1, ZO-2, occludin, claudin induced by glucorticoids
[128,135,136].
The zinc-ﬁnger transcription factors Snail and Slug are suppressors
of the expression of cell–cell adhesion components in different cell
types and play a central role in the epithelium-mesenchyme
transition. Snail binds directly to the E-boxes of the promoters of
claudin and occludin genes, resulting in complete repression of their
promoter activity similar to what has been described for E-cadherin
766 M.S. Balda, K. Matter / Biochimica et Biophysica Acta 1788 (2009) 761–767[46,137–140]. Furthermore, tricellulin, a TJ transmembrane protein
with a similar domain structure as occludin, was identiﬁed as a
protein downregulated by Snail [141]. Additionally, Snail and Slug
upregulation has been linked to reduced expression of TJ proteins
during TGF-beta, HGF and Ras induced transformation
[137,138,140,142–144].
Silencing gene expression by methylation is another important
regulatory mechanism that controls TJ formation as silencing by
methylation of several claudin promoters has been reported in
different type of cancer tissues [145]. In MCF7 breast carcinoma
cells, for example, claudin-6 expression is partially silenced by
promoter CpG island hypermethylation and can be reversed by
combining a demethylator and a histone deacetylase inhibitor [146].
Silencing of Claudin-7 expression in breast cancer cell lines also
correlates with promoter hypermethylation, suggesting a potential
role of Claudin-7 in the progression [147]. Moreover, histone
deacetylase inhibitors also stimulate expression of some TJ proteins
in HeLa cells [148]. However, the relevance of DNA methylation in TJ
proteins gene expression under physiological and developmental
conditions remains to be determined.
An elegant example of regulation of the expression of TJ proteins at
the transcriptional level by adherens junctions in endothelial has
recently been identiﬁed. Vascular endothelial (VE)-cadherin upregu-
lates the expression claudin-5 by releasing the inhibitory activity of
forkhead box factor FoxO1 and the Tcf-4-beta-catenin transcriptional
repressor complex. VE-cadherin acts by inducing the phosphorylation
of FoxO1 through Akt activation and by limiting the translocation of
beta-catenin to the nucleus what provide an explanation of why VE-
cadherin inhibition may cause a marked increase in permeability
[149]. Furthermore, in vivo inactivation of beta-catenin causes blood-
brain-barrier breakdown with down-regulation of claudin-3 but
stabilization of beta-catenin enhances blood-barrier maturation as
well as claudin-3 expression. This can also be reproduced in primary
brain endothelial cells in vitro, as beta-catenin N-terminal truncation
or Wnt3a treatment increases claudin-3 expression and blood-brain-
barrier-type tight junction formation. How beta-catenin regulates the
expression of claudin-3 needs to be demonstrated, but might involve
TCF-LEF binding sites present in the promoter of claudin-3 [150].
In summary, altered expression of TJ proteins seems to bemediated
by different mechanisms and occurs during various physiological or
pathological states. However, the importance of these changes for
disease development and progression, and effects on TJ-associated
signaling mechanisms are still to be analyzed in more detail.
8. Conclusions and perspectives
Several TJ-associated proteins have been linked to different types
of signaling and transcriptional pathways that modulate cell prolif-
eration, differentiation and gene expression. In general, TJs suppress
pathways that stimulate proliferation, allowing differentiation. For
example, ZO-1 expression regulates at least two such pathways by
cytoplasmic sequestration of the transcription factor ZONAB and the
cell cycle kinase cdk4. In agreement, ZO-1 deﬁciency in mice results in
early embryonic lethality. The same is true for ZO-2, which also binds
to several transcription factors. However, we are just starting to
understand their physiological functions during development and in
tissue homeostasis, and we need a better understanding of the roles of
each TJ proteins in signaling and transcriptional pathways and how
they functionally interact with signaling mechanisms originating at
other sites of cell adhesion, such as such as adherens junctions and
integrins. TJs seem to function as a sensor of cell density that is
critically affected by cell transformation. Therefore, to understand
how TJs protein expression is affected during cell differentiation and
how these mechanisms affect TJ-associated signaling mechanism will
be crucial to understand the role of TJs in various diseases including
cancer and inﬂammation.Acknowledgments
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